Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations

Trial Profile

Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Afatinib (Primary) ; Regorafenib (Primary)
  • Indications Gastrointestinal cancer; Head and neck cancer; Non-small cell lung cancer; Tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Dec 2018 to 30 Dec 2018.
    • 13 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
    • 13 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top